Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of human gastric cancer drug treatment organoids

ABSTRACT: Using RNA sequencing, we profile transcriptome dervied from human gastric cancer organoids after drug treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE220137 | GEO | 2023/03/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Human gastric organoids (34 days)

Project description:Human embryonic stem cells (WA01) were differentiated in a step-wise manner into three-dimensional human gastric organoids (hGOs). At day 34 of differentiation, the hGOs were collected and analyzed by RNA-sequencing.

2014-09-09 | E-MTAB-2885 | biostudies-arrayexpress

Human gastric organoids (34 days)

Project description:Human gastric organoids (34 days)

| PRJEB7176 | ENA

Expression data from gastric cancer organoids

Project description:To understand the molecular basis of the acquisition of 5-FU resistance in gastric cancer stem cells, we established 5-FU-resistant gastric cancer organoids. We used microarrays to detail the global program of gene expression underlying 5-FU resistance and maintenance of stem cell properties in gastric cancer.

2020-07-10 | GSE154127 | GEO

5' droplet-based single cell RNA sequencing of human colorectal cancer and normal organoids

Project description:Using 5' droplet-based single cell sequencing, we profiled single cells dervied from human colorectal cancer organoids carrying either APC mutation or RSPO fusion, and paired normal colon organoids for the later.

2020-03-31 | GSE142116 | GEO

Gene expression profile of gastric organoids p53 KO and KD

Project description:Gastric organoids were manipulated to knockout p53

2019-12-10 | GSE141625 | GEO

Analysis of gene expression changes in patient-derived gastric cancer cells after anticancer drug treatment or ALDH1A3 knockdown

Project description:Tumors consist of heterogeneous cell population, containing cancer cell subpopulations with anticancer drug-resistant property, called “persister” cells. To reveal the character of the persister cells, we analyzed gene expression profile of patient-derived gastric cells and residual cancer cells after treatment with 5-FU or SN38, an active metabolite of irinotecan. In our study, we identified ALDH1A3 as a marker and a cell proliferation factor of persister cells. To examine molecular pathways regulated by ALDH1A3, we analyzed gene expression profile of patient-derived gastric JSC15-3 in which ALDH1A3 was knocked down by using shRNAs.

2020-04-14 | GSE139331 | GEO

Expression data from gastric cancer organoids

Project description:Expression data from gastric cancer organoids

| PRJNA645258 | ENA

Gene expression profile of gastric organoids p53 KO and KD

Project description:Gene expression profile of gastric organoids p53 KO and KD

| PRJNA594201 | ENA

Characterization of gastric tumor organoids with specific oncogenic pathway activations

Project description:Gastric cancer ranks the fifth most common malignancy and the third leading cause of cancer related death worldwide. Classical chemotherapy is still the standard treatment in advanced stages, with only two targeted therapies currently in clinical use. Several targeted trials have failed, likely due to missing relevant biomarkers that predict response. Patient derived cancer organoids (PDOs) constitute a three dimensional cell culture system showing self renewal, self organization and regularly unlimited proliferation while faithfully recapitulating many aspects of the tumor they are derived from. Nevertheless, the complex individual mutational landscape hampers the use of PDOs for basic and translational research. We therefore characterized three murine tumor organoid models with defined mutational patterns altering specific oncogenic pathways: a RAS activated (KrasG12D, Tp53R172H), a WNT activated (Apcfl/fl, Tp53R172H) and a diffuse (Cdh1fl/fl, Apcfl/fl) tumor model. The models were analyzed phenotypically, a proteome signature was established and a drug screen performed. The models were morphologically diverse, were characterized by individual protein expression signatures and showed differential drug sensitivities. The developed organoid models allow functional assays as well as pathway specific drug interference testing in a genetically defined setting.

2022-08-22 | PXD022015 | Pride

Gene expression analysis during differentiation into gastric organoids with muscularis mucosa from hiPSC

Project description:We induced gastric organoids with muscularis mucosa from hiPSC.

2022-03-22 | GSE174312 | GEO